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PMyocardial Infarction
Long-Term Outcome and its Predictors
Among Patients With ST-Segment Elevation
Myocardial Infarction Complicated by Shock
Insights From the GUSTO-I Trial
Mandeep Singh, MD,* Jennifer White, MS,† David Hasdai, MD,‡ Patricia K. Hodgson, BA,†
Peter B. Berger, MD,§ Eric J. Topol, MD, Robert M. Califf, MD,† David R. Holmes, JR, MD*
Rochester, Minnesota; Durham, North Carolina; Petah Tikva, Israel; Danville, Pennsylvania;
and La Jolla, California
Objectives This study sought to assess long-term outcome and determine its predictors among 30-day survivors of cardio-
genic shock.
Background Patients with cardiogenic shock have high in-hospital and 30-day mortality, but there are little data about those
who survive beyond 30 days.
Methods We analyzed baseline, in-hospital, and survival data from patients in the U.S. with ST-segment elevation myocar-
dial infarction (STEMI) and cardiogenic shock enrolled in the GUSTO (Global Utilization of Streptokinase and
Tissue-Type Plasminogen Activator for Occluded Coronary Arteries)-I trial and compared them with patients in
the same trial who did not have shock.
Results Of 22,883 patients enrolled in the U.S., shock occurred in 1,891 (8.3%); 953 (50.4%) survived 30 days and 527
(27.8%) survived 11 years. Of 20,992 U.S. patients without shock, 20,360 (96.9%) survived 30 days and 14,131
(67.3%) survived 11 years. After the first year, 2% to 4% of patients died each year regardless of whether they had
cardiogenic shock. Using Cox proportional hazards models, we were able to predict long-term mortality in all U.S.
GUSTO-I 30-day survivors from their baseline demographics and in-hospital complications. The strongest predictors
were diabetes mellitus, cardiogenic shock, hypertension, previous myocardial infarction, current smoking, anterior
infarct, higher Killip class, higher heart rate, and older age; patients75 years were at highest risk. Percutaneous
revascularization during the index hospitalization was associated with a reduced risk of death.
Conclusions Among patients with cardiogenic shock who survive 30 days after STEMI, annual mortality rates of 2% to 4%
approximate those of patients without shock. (J Am Coll Cardiol 2007;50:1752–8) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.101(
i
d
L
t
F
a
e
Tardiogenic shock is of great interest, from its epidemiology
nd pathophysiology to therapeutic strategies when it com-
licates ST-segment elevation myocardial infarction
rom the *Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota;
Duke Clinical Research Institute, Durham, North Carolina; ‡Rabin Medical
enter, Petah Tikva, Israel; §Geisinger Clinic, Danville, Pennsylvania; and the
Scripps Research Institute, La Jolla, California. The GUSTO-I study was funded by
ayer, CIBA-Corning Diagnostics, Genentech, ICI Pharmaceuticals, and Sanofi
harmaceuticals. Dr. Topol was chairman of the study, Dr. Califf was the principal
nvestigator, and Dr. Holmes was a regional director. Each of their institutions
eceived funding through contractual relationships, Duke and Cleveland Clinic with
he 5 sponsors and Mayo Clinic with the Cleveland Clinic, which was the Executive
enter for the GUSTO-I trial. The GUSTO Steering Committee published a
anuscript about patient safety and conflict of interest: J Am Coll Cardiol 1992;19:
123–8.A
Manuscript received January 26, 2007; revised manuscript received April 16, 2007,
ccepted April 30, 2007.STEMI) (1–5). Shock accounts for two-thirds of all
n-hospital mortality from STEMI, most within the first 30
ays, although it occurs in only 4% to 7% of patients (6).
ittle is known about 30-day survivors of shock.
See page 1759
Predictors of short-term and 1-year outcomes in pa-
ients with cardiogenic shock have been described (1,7).
ew publications report long-term outcome or predictors,
lthough such data would help optimize treatment strat-
gies (8,9).
The GUSTO (Global Utilization of Streptokinase and
issue-Type Plasminogen Activator for Occluded Coronary
rteries)-I trial presents an opportunity to evaluate long-
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October 30, 2007:1752–8 Long-Term Survival of Shock Complicating STEMIerm outcome in fibrinolytic-eligible patients with and
ithout cardiogenic shock (10). We describe 11-year out-
omes of patients with STEMI with and without cardiogenic
hock enrolled in the U.S. in the GUSTO-I trial who
urvived 30 days after the index event.
ethods
tudy population. The GUSTO-I trial was a multicenter, mul-
inational trial of 41,021 patients with STEMI who pre-
ented with1 mm ST-segment elevation in2 limb leads
r 2 mm in 2 contiguous precordial leads 20 min to 6 h
fter symptom onset between 1990 and 1993 (10). Exclu-
ion criteria were previous stroke, active bleeding, previous
reatment with streptokinase or anistreplase, recent trauma
r major surgery, previous participation in the trial, or
oncompressible vascular punctures. Patients with severe,
ncontrolled hypertension (systolic blood pressure 180
m Hg, unresponsive to therapy) had a relative contrain-
ication to enrollment. There was no upper age limit. The
rimary end point was all-cause 30-day mortality. Patients
ave informed consent, and the institutional review board at
ach hospital approved the protocol.
The GUSTO-I trial did not exclude patients with car-
iogenic shock due to any cause and thus did not restrict the
efinition of shock to left ventricular pump failure. Shock was
efined as systolic blood pressure 90 mm Hg for 1 h not
esponsive to fluid administration alone, thought to be second-
ry to cardiac dysfunction, and associated with signs of
ypoperfusion or cardiac index 2.2 l/min/mm2 and pul-
onary capillary wedge pressure 18 mm Hg.
ollow-up. To obtain long-term outcome data from the
USTO-I trial, we used the National Death Index (NDI),
estricting us to following up only patients from the U.S.
For all U.S. patients who survived 30 days, specific data
Social Security number, birth date, gender, first name, last
ame) were submitted to the NDI and matched against its
ecords to eliminate patients who had died in the interim.
hen all data elements matched precisely, patients received
igh probability scores from the NDI, and we considered
hem nonsurvivors. Occasionally, the NDI assigned slightly
ower probabilities to patients who matched on most but not
ll of the elements (e.g., a minor difference in the spelling of
patient’s last name but all other factors matched exactly).
e also considered such patients to be late deaths. Mini-
um follow-up for the surviving patients was 9.9 years; 95%
ere followed up for at least 11 years. Events were censored
t 11 years for this analysis.
tatistical analysis. We present stratified Kaplan-Meier
stimates for mortality rates by baseline characteristics and
ndex hospitalization events. For continuous variables, suit-
ble cut points were chosen based on the distribution of the
ata.
Univariable analysis for trends was performed with Cox
roportional hazard models. For categorical variables, indi-
ator variables were formed. Univariable models to test (ategorical variables with more
han 2 classes used all indicators
ess 1 category for the reference
roup. In the case of myocardial
nfarction (MI) location, patients
ere assigned to the hierarchy of
nterior, inferior, and other. Re-
ults were interpreted as statisti-
ally significant when p  0.05.
verall long-term mortality was
epicted with 95% confidence intervals using the Kaplan-
eier method.
Multivariable Cox proportional hazards survival model-
ng techniques were used to develop a predictive model for
ong-term mortality risk. All variables listed in Tables 1 and
were considered in the model. A stepwise selection process
as used, augmented by bootstrap techniques to alleviate
hortcomings of stepwise selection (11,12). The process
onsisted of creating 200 bootstrap populations using ran-
om selection of study patients, with replacement. Stepwise
ox regression models were run on all bootstrap samples,
nd factors were confirmed for inclusion in the final model
ased on the overall frequency of their retention in the
odels. This method was used in an iterative fashion to
efine and confirm selection decisions.
Linearity assumptions were checked, and transformations
f continuous variables were created as needed. For all
ontinuous independent variables, a restricted cubic spline
as fit and plotted against the dependent variable (outcome
f death) (13). Plots of the spline-transformed continuous
ariables and the log-hazard ratio for death were produced.
hen these plots showed a linear relationship, no transfor-
ations were considered. If the plots depicted nonlinear
elationships, simple transformations such as inverse, poly-
omial, natural logarithm, or linear splines were pursued.
he only continuous variable retained in the final multiva-
iable model for long-term survival was age. The transfor-
ation that worked best was a linear spline with the cut
oint at age 55 years; this transformation forms 2 indepen-
ent continuous variables at the point where the relation-
hip to outcome changes.
esults
f the 22,883 U.S. patients, 1,891 (8.3%) arrived in or
eveloped shock during the index hospitalization. At 30
ays, 20,360 patients (88.9%) without and 953 (50.4%) with
hock were alive; their baseline characteristics are presented
n Table 3. After a median of 11 years, 14,131 30-day
urvivors (69.4%) without and 527 (55.2%) with shock
emained alive.
Among all 30-day survivors, risk factors for 11-year
ortality were as expected: older age, anterior MI, worse
illip class, higher heart rate, and adverse medical history
Abbreviations
and Acronyms
MI  myocardial infarction
NDI  National Death
Index
STEMI  ST-segment
elevation myocardial
infarctionTable 1). Patients with in-hospital complications were
KT
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Table 1 Kaplan-Meier Mortality Estimates at 11 Years for All GUSTO-ITrial 30-Day Survivors in the U.S. Stratified by Baseline Characteristics
Variable Category
Kaplan-Meier Estimated
Mortality Rate* (%) 95% Confidence Interval Chi-Square p Value†
Age 65 yrs No 20.5 (19.85–21.21) 2,153.47 0.0001
Yes 49.9 (48.83–51.06)
Male gender No 36.2 (34.99–37.52) 90.45 0.0001
Yes 29.5 (28.8–30.23)
Weight 80 kg No 34.5 (33.59–35.48) 100.60 0.0001
Yes 28.4 (27.6–29.25)
Smoking Current 28.3 (27.43–29.25) 71.02 0.0001
Former 34.0 (32.8–35.22)
Never 33.0 (31.85–34.25)
Shock No 30.6 (29.97–31.23) 146.12 0.0001
Yes 44.8 (41.64–47.97)
Comorbid conditions
Diabetes mellitus No 28.4 (27.74–29.06) 473.36 0.0001
Yes 46.4 (44.72–48.08)
Hypertension No 27.1 (26.3–27.87) 244.20 0.0001
Yes 37.0 (36.02–38.03)
Hyperlipidemia No 33.3 (32.53–34.17) 73.91 0.0001
Yes 27.7 (26.73–28.7)
MI location
Anterior 35.1 (34.08–36.22) 99.23 0.0001
Inferior 28.9 (28.1–29.66)
Other 31.4 (27.78–35.2)
History
PTCA No 31.0 (30.32–31.6) 14.33 0.0002
Yes 35.6 (32.98–38.4)
CABG No 30.0 (29.4–30.66) 338.46 0.0001
Yes 52.7 (49.83–55.6)
MI No 28.1 (27.48–28.8) 583.03 0.0001
Yes 47.2 (45.49–48.83)
Angina No 28.7 (27.99–29.5) 121.72 0.0001
Yes 35.8 (34.74–36.94)
CVD No 30.7 (30.09–31.35) 171.56 0.0001
Yes 56.3 (51.65–60.9)
Baseline variables
Systolic BP 120 mm Hg No 30.3 (29.26–31.34) 3.77 0.0520
Yes 31.6 (30.83–32.41)
Diastolic BP 75 mm Hg No 32.3 (31.34–33.26) 11.04 0.0009
Yes 30.1 (29.31–30.99)
Pulse 70 beats/min No 28.3 (27.29–29.23) 65.33 0.0001
Yes 33.2 (32.35–34)
Killip class I 29.2 (28.58–29.88) 483.56 0.0001
II 45.4 (43.31–47.52)
III 65.0 (57.51–71.75)
IV 54.2 (43.43–64.62)
Treatment variables
Time to treat 2 h No 25.8 (24.68–26.98) 99.73 0.0001
Yes 33.0 (32.26–33.77)
Thrombolytic t-PA 31.2 (30.03–32.48) 1.22 0.7479
SK IV Hep 30.8 (29.6–32.05)
t-PA SK 31.4 (30.18–32.65)
SK SubQ Hep 31.6 (30.33–32.92)
Stratified Kaplan-Meier mortality rates estimated at 11 years. †p value from log rank test.
BP blood pressure; CABG coronary artery bypass grafting; CVD cerebrovascular disease; Hep heparin; IV intravenous; MImyocardial infarction; PTCA percutaneous transluminal coronary
ngioplasty; SK  streptokinase; SubQ  subcutaneous; t-PA  tissue plasminogen activator.
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October 30, 2007:1752–8 Long-Term Survival of Shock Complicating STEMIore likely to die in the ensuing 11 years, whereas those
eceiving percutaneous revascularization during the index
ospitalization were less likely to die (Table 2).
For all 30-day survivors, Figure 1 shows hazard ratio
esults of univariable Cox regression modeling of the vari-
bles associated with higher long-term mortality, which did
ot differ between patients with and without shock. Increas-
ng age, lower body weight, comorbid conditions, adverse
istory, anterior MI, in-hospital complications, and longer
ospital stay were all associated with adverse long-term
rognosis. Killip class I versus IV at baseline and coronary
ngioplasty during index hospitalization were associated
ith long-term survival.
For all patients, regardless of shock status, age 75 years
t enrollment was associated with high mortality at 30 days
10.9% nonshock and 68.1% shock patients) and, among
0-day survivors, at 11 years (68.2% and 65.6%, respec-
ively) (Table 4).
Figure 2 depicts the Kaplan-Meier curves for 11-year
ortality for all 30-day survivors. Beginning in the second
ear, mortality rates were 2% to 4% per year for all patients
egardless of shock status (Fig. 3).
For all 30-day survivors, we used multivariable Cox
roportional hazard regression analysis to determine the
nfluence of baseline clinical variables and revascularization
n long-term outcome. Table 5 shows variables associated
ith long-term mortality: shock, hypertension, diabetes,
urrent smoking, anterior MI, previous MI, higher heart
ate, and worse Killip class. The influence of increasing age
ad greater impact on outcome for patients 55 years at
Kaplan-Meier Mortality Estimates for All GUSTOSurvivors in the U.S. Based on Events During In
Table 2 Kaplan-Meier Mortality Estimates foSurvivors in the U.S. Based on Even
Variable Category
Kaplan-Meier Es
Mortality Rat
Reinfarction (in-hospital)‡ No 31.2
Yes 33.6
Stroke (in-hospital)‡ No 31.0
Yes 58.2
Severe bleed (in-hospital)‡ No 31.1
Yes 44.4
Hospital stay 12 days No 27.8
Yes 40.7
IABP No 30.8
Yes 39.0
Index CABG No 31.2
Yes 32.0
Index PTCA No 34.6
Yes 24.1
*Stratified Kaplan-Meier mortality rates estimated at 11 years. †p valu
1) recurrent ischemic symptoms lasting 15 min after resolution of i
second evaluation of cardiac enzymes to greater than the upper li
angiographic reocclusion of a documented previously patent infarct-re
cerebral infarct with conversion to hemorrhagic, a nonhemorrhagic
independent Stroke Review Committee (10). Severe bleeding either wa
treatment (10).
CABG  coronary artery bypass grafting; IABP  intra-aortic ballooandomization than on those 55 years. giscussion
he most important finding of the present study is that the
nnual mortality of 2% to 4% was similar among U.S.
USTO-I trial patients with and without cardiogenic
hock 2 years to 11 years after STEMI. A second notable
nding is that the predictors of long-term outcome were
imilar regardless of shock status, underscoring the need for
ggressive strategies to lower the early hazard associated
ith shock.
This annual mortality rate of 2% to 4% is similar to
0-year data from the ISIS (International Study of Infarct
urvival)-2 trial, with annual mortality of approximately 4%
fter the first year irrespective of shock status (14). The
nnual mortality in similar patients enrolled in the GISSI
Gruppo Italiano per lo Studio della Sopravvivenza
ell’Infarto Miocardico)-I study was 3.6% (15).
Two studies have published 1-year survival data in shock
atients (1,7). The GUSTO-I trial reported survival of 88%
mong all shock patients worldwide who survived 30 days;
urvival was 97% in patients without shock (1). The
HOCK (Should We Emergently Revascularize Occluded
oronaries for Cardiogenic Shock) trial of patients with
redominantly left ventricular failure reported 1-year sur-
ival of 46.7% in the early revascularization group, signifi-
antly better than 33.6% in the initial medical stabilization
roup (7).
Six-year follow-up data are available for the SHOCK and
RACE (Trandolapril Cardiac Evaluation) studies (16,17).
he SHOCK study survival was 20% and 33% for, respec-
ively, the early revascularization and initial stabilization
l 30-Dayospitalization
GUSTO-I Trial 30-Day
uring Index Hospitalization
ed
95% Confidence Interval Chi-Square p Value†
(30.55–31.81) 2.28 0.13
(30.24–37.23)
(30.34–31.59) 130.25 0.0001
(51.64–64.43)
(30.5–31.75) 18.70 0.0001
(37.76–51.19)
(27.07–28.48) 345.76 0.0001
(39.38–42.03)
(30.21–31.49) 37.93 0.0001
(36.07–42.1)
(30.49–31.83) 0.03 0.85
(30.36–33.76)
(33.86–35.41) 246.61 0.0001
(23.05–25.09)
log-rank test. ‡Reinfarction (from the GUSTO-I trial case report form):
yocardial infarction; 2) new ST-T-wave changes or new Q waves; 3) a
normal (or by 20% increase if enzymes already elevated); and 4)
rtery. Strokes were classified as caused by a primary hemorrhage, a
l infarct, or an unknown cause. Stroke data were reviewed by an
erebral or resulted in substantial hemodynamic compromise requiring
; PTCA  percutaneous transluminal coronary angioplasty.-I Triadex H
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ts D
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s
t
s
p
n
t
v
e
F
2
s
r
m
e
r
a
BT
B

p
3
1756 Singh et al. JACC Vol. 50, No. 18, 2007
Long-Term Survival of Shock Complicating STEMI October 30, 2007:1752–8hock and 12% in shock patients. By contrast, GUSTO-I
rial 11-year survival was 67% in nonshock and 28% in
hock patients.
The favorable long-term outlook for U.S. GUSTO-I trial
atients with shock 2 to 11 years after hospital dismissal was
ot anticipated. Shock has traditionally been thought to be
he result of an irreversible loss of a major amount of left
entricular myocardium, leading to high mortality. How-
ver, several observations have failed to support this concept.
irst, the average ejection fraction in the SHOCK trial was
aseline Clinical Characteristics of All GUSTO-Irial Patients in the U.S. Stratified by Shock Status
Table 3 Baseline Clinical Characteristics of All GUSTO-ITrial Patients in the U.S. Stratified by Shock Status
No Shock
(n  20,360)
Shock
(n  953)
Age (yrs) 60.2 64.8
Female gender (%) 25.6 33.9
Weight (kg) 81.0 78.0
Height (cm) 172.7 172.7
Heart rate (beats/min) 73.0 77.0
Systolic BP (mm Hg) 128.0 116.0
Diastolic BP (mm Hg) 78.0 71.0
History of CAD (%) 49.3 45.4
Killip class (%)
I 89.5 71.5
II 9.8 16.3
III 0.7 3.5
IV 0.0 8.8
Hypertension (%) 41.9 42.8
Diabetes (%) 15.9 15.8
Current smoker (%) 44.4 43.7
Former smoker (%) 27.8 29.8
Hyperlipidemia (%) 38.5 35.4
Time to treatment (h) 2.7 2.6
MI location (%)
Anterior 35.9 43.4
Inferior 61.2 54.6
Other 2.9 2.0
Prior MI (%) 16.1 18.3
Previous angina (%) 34.7 35.0
Previous CVD (%) 2.0 3.7
Prior CABG (%) 5.4 6.6
Prior PTCA (%) 5.7 4.6
Index CABG (%) 13.2 22.6
Index PTCA (%) 31.9 36.2
Stroke (in-hospital) (%) 1.0 3.1
Severe bleed (%) 12.7 42.9
IABP (%) 3.2 38.6
P blood pressure; CAD coronary artery disease; CABG coronary artery bypass grafting; CVD
cerebrovascular disease; IABP intra-aortic balloon pump; MImyocardial infarction; PTCA
ercutaneous transluminal coronary angioplasty.
0-Day and Long-Term Mortality for All GUSTO-I Trial Patients in th
Table 4 30-Day and Long-Term Mortality for All GUSTO-I Trial P
Age <75 yrs
Mortality No Shock
30 days 375/18,635 (2.0%) 6111 yrs (in 30-day survivors) 4,798/18,260 (26.3%) 327/809% (7). Second, at 1 year, many survivors of cardiogenic
hock have good functional status (8). It may be that
esolution of severe ischemia and/or neurohormonal abnor-
alities can explain the potential reversibility of shock. New
vidence points to involvement of a systemic inflammatory
esponse, activation of complement, release of cytokines,
nd expression of inducible nitric oxide synthase in the
Figure 1 Hazard Ratios for All 30-Day Survivors
Hazard ratios with (red circles) and without (blue squares) cardiogenic shock.
Factors analyzed include baseline characteristics, cardiac history, treatment
group, and procedures undergone during index hospitalization. All continuous
variables (age, weight, height, heart rate, and systolic and diastolic blood pres-
sure) were measured in units of 1 (e.g., respectively, 1 year, 1 kg, 1 cm, 1
beat/min, and 1 mm Hg), so that patients with a variable that measured 1 U
greater than another patient had a hazard of mortality as reflected in the fig-
ure. For example, a nonshock 65-year-old patient had a 1.06 greater hazard of
dying than a nonshock 64-year-old patient. BP  blood pressure; CABG  coro-
nary artery bypass grafting; CVD  cerebrovascular disease; dia  diastolic;
IABP  intra-aortic balloon pump; IV Hep  intravenous heparin; MI  myocar-
dial infarction; PTCA  percutaneous transluminal coronary angioplasty; SK 
streptokinase; SubQ Hep  subcutaneous heparin; sys  systolic; t-PA  tis-
sue plasminogen activator.
. Stratified by Shock Status and Age
ts in the U.S. Stratified by Shock Status and Age
Age >75 yrs
hock No Shock Shock
12 (43.2%) 255/2,349 (10.9%) 323/474 (68.1%)e U.S
atien
S
0/1,42 (40.8%) 1,428/2,094 (68.2%) 99/151 (65.6%)
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ardiogenic shock (6).
We found the significant predictors of long-term mor-
ality to include expected factors: advancing age, traditional
isk factors (including current smoking), and evidence of a
arge infarct or left ventricular dysfunction. These variables
lso adversely affected prognosis at 1 year with the exception
f current smoking; there is no cogent explanation for this
atter observation. Patients who continued to smoke likely
ared better in the short term, as shown by less need for
dditional revascularization procedures (18,19). During
onger periods, however, smokers have higher adverse car-
iovascular events (19). The other predictors of long-term
Figure 2 Kaplan-Meier Mortality Curve
in 30-Day Survivors of STEMI
The Kaplan-Meier mortality estimate at 11 years is 44.8% (95% confidence
interval 41.6 to 47.9) in patients with (red line)and 30.6% (95% confidence
interval 29.9 to 31.2) in patients without (blue line) shock. STEMI  ST-seg-
ment elevation myocardial infarction.
ultivariable Cox Regression Model for All GUSTO-I Trial 30-Day Su
Table 5 Multivariable Cox Regression Model for All GUSTO-I Tr
Label Hazard Ratio
95% Lower Confidence Lim
for Hazard Ratio
Shock 1.45 1.311
Age 55 yrs (spline)* 1.03 1.017
Age 55 yrs (spline)* 1.08 1.076
Prior MI 1.56 1.464
Diabetes mellitus 1.58 1.491
Prior CABG 1.58 1.440
Anterior MI location 1.16 1.106
Index CABG or PTCA 0.76 0.723
Current smoker 1.62 1.534
Pulse (units of 10) 1.09 1.078
Hypertension 1.23 1.172
Male gender 1.21 1.144
Previous CVD 1.41 1.239
Killip I (baseline) 0.74 0.695Linear spline term for age: there are significant and different linear increases in the risk of mortality as ag
CABG  coronary artery bypass grafting; CVD  cerebrovascular disease; MI  myocardial infarction;ortality in GUSTO-I trial 30-day survivors are similar to
isk factors in patients presenting without ST-segment
levation and cardiogenic shock (20–22).
The SHOCK investigators noted an age–treatment in-
eraction so that a treatment benefit was apparent only for
atients 75 years, among whom 1-year survival was 55%
early revascularization) versus 33% (initial medical stabili-
ation). Current American College of Cardiology/American
eart Association guidelines recommend the use of intra-
ortic balloon pumping and early surgical or percutaneous
evascularization for suitable shock patients 75 years if it
an be performed within 18 h of shock (23). Because the
USTO-I trial had no exclusion criterion for older age, we
ere able to observe patients 75 years at enrollment, a
ubgroup not addressed in contemporary guidelines. Among
ll U.S. patients 75 years with cardiogenic shock who
Figure 3 Bar Graph Showing Annual Mortality in
STEMI Patients Presenting With and Without Shock
Mortality rates beyond the first year are similar.
STEMI  ST-segment elevation myocardial infarction.
rs in the U.S.
-Day Survivors in the U.S.
95% Upper Confidence Limit
for Hazard Ratio Wald Chi-Square p Value
1.615 49.6 0.0001
1.033 37.8 0.0001
1.084 1,858.3 0.0001
1.658 196.4 0.0001
1.680 225.5 0.0001
1.736 92.9 0.0001
1.225 33.8 0.0001
0.802 107.9 0.0001
1.718 278.7 0.0001
1.109 153.2 0.0001
1.297 65.5 0.0001
1.281 43.6 0.0001
1.615 26.4 0.0001
0.796 73.8 0.0001rvivo
ial 30
ite increases for patients under the age of 55 years and over the age of 55 years at randomization.
PTCA  percutaneous transluminal coronary angioplasty.
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Long-Term Survival of Shock Complicating STEMI October 30, 2007:1752–8urvived 30 days, the hazard ratio for 11-year mortality was
.05. Older age itself carried substantial risk, as 68.2% of
onshock and 65.6% of shock patients who survived the first
0 days died by 11 years.
tudy limitations. Our results pertain only to patients who
resented with STEMI and were treated with fibrinolysis.
hus, caution is urged in extrapolating these results to shock
atients who are fibrinolytic-ineligible and to patients with
hock after non-STEMI. Given the use of the NDI to
etermine how many patients from the GUSTO-I trial had
ied, there were limitations to the follow-up data; informa-
ion about nonfatal cardiovascular events, other medical
onditions and treatments, or the frequency with which
atients underwent revascularization after 30 days could not
e collected.
Another limitation is the derivation from an older data-
et. With advances in technology, pharmacotherapy, and
anagement of patients presenting with STEMI including
ardiogenic shock, long-term outcomes from this study may
e less relevant today. Although advances in primary angio-
lasty and adjunctive pharmacotherapy may make our re-
ults less applicable, this study provides a benchmark against
hich current strategies can be compared.
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